XM không cung cấp dịch vụ cho cư dân của Mỹ.
A
A

AstraZeneca


Tin tức

US natgas slips over 1% in volatile trade on less cooling demand

UPDATE 1-US natgas slips over 1% in volatile trade on less cooling demand Adds closing price By Rahul Paswan Sept 18 (Reuters) - U.S. natural gas futures fell more than 1% on Wednesday in a volatile trading, on fewer warmer-than-normal weather forecasts than previously expected, even as production was slow to ramp up to match demand after Hurricane Francine.
A
N

US natgas slips over 1% in volatile trade on less cooling demand

US natgas slips over 1% in volatile trade on less cooling demand By Rahul Paswan Sept 18 (Reuters) - U.S. natural gas futures fell more than 1% on Wednesday in a volatile trading, on fewer warmer-than-normal weather forecasts than previously expected, even as production was slow to ramp up to match demand after Hurricane Francine. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange fell 2.7 cents or 1.2% to $2.30 per million British thermal units (mmBtu) by 11:0
A
N

AstraZeneca Says Fasenra Approved In US For Eosinophilic Granulomatosis With Polyangiitis

BRIEF-AstraZeneca Says Fasenra Approved In US For Eosinophilic Granulomatosis With Polyangiitis Sept 18 (Reuters) - AstraZeneca PLC AZN.L : FASENRA EGPA US FDA APPROVAL FASENRA APPROVED IN US FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS FDA APPROVAL BASED ON POSITIVE MANDARA PHASE III TRIAL RESULTS Source text for Eikon: ID:nRSR6617Ea Further
A

US natgas slips 2% as output rises after Hurricane Francine

UPDATE 1-US natgas slips 2% as output rises after Hurricane Francine Adds comment and closing price By Rahul Paswan and Brijesh Patel Sept 17 (Reuters) - U.S. natural gas futures fell 2% on Tuesday after hitting a more than two-month high earlier in the session , a s Gulf of Mexico producers slowly ramp up production after Hurricane Francine, easing concerns over supply and prompting some profit taking.
A
N

US natgas hits over two-month high on warmer weather, higher demand view

US natgas hits over two-month high on warmer weather, higher demand view By Rahul Paswan Sept 17 (Reuters) - U.S. natural gas futures rose to a more than two-month high on Tuesday, supported by higher demand forecasts for the next week and warmer weather outlook which could boost the amount of gas power generators burn. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 5.2 cents or 2.2% to $2.43 per million British thermal units (mmBtu) at 10:16 a.m.
A
N

US natgas rises 3% on higher demand outlook, output cut

UPDATE 1-US natgas rises 3% on higher demand outlook, output cut Adds closing price, add details By Rahul Paswan Sept 16 (Reuters) - U.S. natural gas futures rose 3 % on Monday, buoyed by forecasts for higher demand over the next week, while the market also factored in production cuts due to last week's storm. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 6.8 cents or 3% to settle at $2.373 per million British thermal units (mmBtu).
A
N

US natgas rises over 2% on higher demand outlook, supply woes

US natgas rises over 2% on higher demand outlook, supply woes By Rahul Paswan Sept 16 (Reuters) - U.S. natural gas futures rose more than 2% on Monday, buoyed by forecasts for higher demand over the next week, while the market also factored in production cuts due to last week's storm. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose 5.8 cents or 2.5% to $2.36 per million British thermal units (mmBtu) at 10:35 a.m.
A
N

Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line

UPDATE 1-Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line Adds details on supply in paragraphs 4 and 6, background throughout Sept 16 (Reuters) - Sanofi SASY.PA and partner AstraZeneca AZN.L have received approval from the U.S. Food and Drug Administration for a manufacturing line for their preventive respiratory syncytial virus (RSV) therapy, the French drugmaker said on Monday.
A
S

US FDA approves manufacturing line for Sanofi's preventive RSV therapy

US FDA approves manufacturing line for Sanofi's preventive RSV therapy Sept 16 (Reuters) - Sanofi SASY.PA said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca's AZN.L preventive respiratory syncytial virus (RSV) therapy. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswa
A
S

Imfinzi® (Durvalumab) Plus Imjudo® (Tremelimumab-Actl) Demonstrated Unprecedented Overall Survival In Advanced Liver Cancer With One In Five Patients Surviving Five Years In Himalaya Phase Iii Trial

BRIEF-Imfinzi® (Durvalumab) Plus Imjudo® (Tremelimumab-Actl) Demonstrated Unprecedented Overall Survival In Advanced Liver Cancer With One In Five Patients Surviving Five Years In Himalaya Phase Iii Trial Sept 16 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI® (DURVALUMAB) PLUS IMJUDO® (TREMELIMUMAB-ACTL) DEMONSTRATED UNPRECEDENTED OVERALL SURVIVA
A

AstraZeneca's Imfinzi Plus Imjudo Demonstrated Overall Survival In Advanced Liver Cancer

BRIEF-AstraZeneca's Imfinzi Plus Imjudo Demonstrated Overall Survival In Advanced Liver Cancer Sept 16 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI PLUS IMJUDO DEMONSTRATED UNPRECEDENTED OVERALL SURVIVAL IN ADVANCED LIVER CANCER WITH ONE IN FIVE PATIENTS SURVIVING FIVE YEARS IN HIMALAYA PHASE III TRIAL Source text for Eikon: ID:nWkr56t86z Further co
A

Astrazeneca Says Imfinzi Perioperative Regimen Reduced The Risk Of Recurrence By 32% And The Risk Of Death By 25%

BRIEF-Astrazeneca Says Imfinzi Perioperative Regimen Reduced The Risk Of Recurrence By 32% And The Risk Of Death By 25% Sept 15 (Reuters) - AstraZeneca PLC AZN.L : IMFINZI® (DURVALUMAB) PERIOPERATIVE REGIMEN REDUCED THE RISK OF RECURRENCE BY 32% AND THE RISK OF DEATH BY 25% VERSUS. NEOADJUVANT CHEMOTHERAPY ALONE IN MUSCLE-INVASIVE BLADDER CANCER I
A

US natgas drops on profit taking after hitting 2-month high

UPDATE 1-US natgas drops on profit taking after hitting 2-month high Adds analyst comment, closing prices By Sherin Elizabeth Varghese Sept 13 (Reuters) - U.S. natural gas futures fell on Friday, as traders took profits after prices rose to a two-month high early, supported by higher demand forecasts and a drop in output in recent days due to Hurricane Francine.
A
N

Moffitt Cancer Center Announces Strategic Collaboration With Astrazeneca To Accelerate Oncology Cell Therapies

BRIEF-Moffitt Cancer Center Announces Strategic Collaboration With Astrazeneca To Accelerate Oncology Cell Therapies Sept 13 (Reuters) - AstraZeneca PLC AZN.L : MOFFITT CANCER CENTER ANNOUNCES STRATEGIC COLLABORATION WITH ASTRAZENECA TO ACCELERATE ONCOLOGY CELL THERAPIES Source text for Eikon: ID:nBw9whrNpa Further company coverage: AZN.L
A

US natgas hits two-month high on output drop, higher demand view

US natgas hits two-month high on output drop, higher demand view By Sherin Elizabeth Varghese Sept 13 (Reuters) - U.S. natural gas futures rose to a two-month high on Friday, supported by higher demand forecasts and a drop in output in recent days as Hurricane Francine prompted oil and gas producers to cut production. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange were little changed at $2.36 per million British thermal units (mmBtu) at 10:27 a.m.
A
N

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

European stocks wrap up week on a high note; focus shifts to Fed

UPDATE 2-European stocks wrap up week on a high note; focus shifts to Fed For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window France's inflation at 0.2% in Aug. AstraZeneca down after Deutsche Bank downgrades Worldline plunges on another guidance cut, CEO exit STOXX 600 up 0.7% Updated at 1550 GMT By Shubham Batra Sept 13 (Reuters) - European stocks rounded off the week on a positive note, supported by technology, real estate and mining shar
A
S
E
F
U
G

AstraZeneca hits more than 7-week low after Deutsche Bank downgrades

BUZZ-AstraZeneca hits more than 7-week low after Deutsche Bank downgrades ** Shares of AstraZeneca AZN.L fall 1.4% to 11,874 pence, lowest since July 24 ** AZN second biggest percentage loser on the benchmark FTSE 100 index .FTSE ** Deutsche Bank cuts rating to "sell" from "hold" and target price to 10,500p from 11,000p ** Twenty-one of 29 brokerag
A
U

Alstom, Siemens, Tesco

EUROPE RESEARCH ROUNDUP-Alstom, Siemens, Tesco Sept 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alstom, Siemens and Tesco, on Friday. HIGHLIGHTS * Alstom ALSO.PA : HSBC raises target price to EUR 26 from EUR 24 * Hexagon AB HEXAB.ST : HSBC cuts target price to SEK 110 from SEK 120 * Siemens AG SIEGN.DE : HSBC cuts target price to EUR 140 from EUR 150 * Tesco TSCO.L : Citigroup raises target price to 425p from 350p * Travis P
A
A
A
B
B
B
C
C
C
D
D
E
E
F
H
H
I
K
L
L
S
S
S
S
T
T
P
A
A
F
S
U

US natgas rises nearly 5% on smaller-than-expected storage build

UPDATE 2-US natgas rises nearly 5% on smaller-than-expected storage build Adds closing prices Sept 12 (Reuters) - U.S. natural gas futures rose nearly 5% on Thursday on a smaller-than-expected storage build last week, while traders assessed the impact on supply after oil and gas producers cut output due to Hurricane Francine. Front-month gas futures NGc1 for October delivery on the New York Mercantile Exchange rose by 8.7 cents, or about 3.8%, to settle at $2.357 per million British thermal unit
A
N



Các điều kiện

Các tài sản phổ thông

Khước từ trách nhiệm: các tổ chức thuộc XM Group chỉ cung cấp dịch vụ khớp lệnh và truy cập Trang Giao dịch trực tuyến của chúng tôi, cho phép xem và/hoặc sử dụng nội dung có trên trang này hoặc thông qua trang này, mà hoàn toàn không có mục đích thay đổi hoặc mở rộng. Việc truy cập và sử dụng như trên luôn phụ thuộc vào: (i) Các Điều kiện và Điều khoản; (ii) Các Thông báo Rủi ro; và (iii) Khước từ trách nhiệm toàn bộ. Các nội dung như vậy sẽ chỉ được cung cấp dưới dạng thông tin chung. Đặc biệt, xin lưu ý rằng các thông tin trên Trang Giao dịch trực tuyến của chúng tôi không phải là sự xúi giục, mời chào để tham gia bất cứ giao dịch nào trên các thị trường tài chính. Giao dịch các thị trường tài chính có rủi ro cao đối với vốn đầu tư của bạn.

Tất cả các tài liệu trên Trang Giao dịch trực tuyến của chúng tôi chỉ nhằm các mục đích đào tạo/cung cấp thông tin và không bao gồm - và không được coi là bao gồm - các tư vấn tài chính, đầu tư, thuế, hoặc giao dịch, hoặc là một dữ liệu về giá giao dịch của chúng tôi, hoặc là một lời chào mời, hoặc là một sự xúi giục giao dịch các sản phẩm tài chính hoặc các chương trình khuyến mãi tài chính không tự nguyện.

Tất cả nội dung của bên thứ ba, cũng như nội dung của XM như các ý kiến, tin tức, nghiên cứu, phân tích, giá cả, các thông tin khác hoặc các đường dẫn đến trang web của các bên thứ ba có trên trang web này được cung cấp với dạng "nguyên trạng", là các bình luận chung về thị trường và không phải là các tư vấn đầu tư. Với việc các nội dung đều được xây dựng với mục đích nghiên cứu đầu tư, bạn cần lưu ý và hiểu rằng các nội dung này không nhằm mục đích và không được biên soạn để tuân thủ các yêu cầu pháp lý đối với việc quảng bá nghiên cứu đầu tư này và vì vậy, được coi như là một tài liệu tiếp thị. Hãy chắc chắn rằng bạn đã đọc và hiểu Thông báo về Nghiên cứu Đầu tư không độc lập và Cảnh báo Rủi ro tại đây liên quan đến các thông tin ở trên.

Cảnh báo rủi ro: Vốn của bạn bị rủi ro. Các sản phẩm có đòn bẩy có thể không phù hợp với tất cả mọi người. Hãy xem kỹ Thông báo rủi ro của chúng tôi.